The Second Multicenter Hemophilia Cohort Study

December 14, 2019 updated by: National Cancer Institute (NCI)
The Second Multicenter Hemophilia Cohort Study (MHCS-II) will evaluate and prospectively follow approximately 4500 persons with hemophilia who were exposed to hepatitis C virus (HCV). The vast majority will have been infected with HCV, and approximately 1/3 will have been infected with human immunodeficiency virus (HIV). Primary objectives are to quantify the rates of liver decompensation, hepatocellular carcinoma, and non-Hodgkin lymphoma and to evaluate candidate clinical, genetic, virologic, serologic and immunologic markers that are likely to be on the causal pathway for these conditions. Candidate clinical and laboratory markers will be examined longitudinally to define changes over time and their relationships to one another. Collaborative studies will focus on genome scanning and evaluation of candidate genetic loci for susceptibility or resistance to HCV and HIV infections or to the diseases that result from these infections. Additional studies will identify response and complication rates of various anti-HCV and anti-HIV regimens in the setting of comprehensive clinical care of persons with hemophilia.

Study Overview

Detailed Description

The Second Multicenter Hemophilia Cohort Study (MHCS-II) will evaluate and prospectively follow approximately 4500 persons with hemophilia who were exposed to hepatitis C virus (HCV). The vast majority will have been infected with HCV, and approximately 1/3 will have been infected with human immunodeficiency virus (HIV). Primary objectives are to quantify the rates of liver decompensation, hepatocellular carcinoma, and non-Hodgkin lymphoma and to evaluate candidate clinical, genetic, virologic, serologic and immunologic markers that are likely to be on the causal pathway for these conditions. Candidate clinical and laboratory markers will be examined longitudinally to define changes over time and their relationships to one another. Collaborative studies will focus on genome scanning and evaluation of candidate genetic loci for susceptibility or resistance to HCV and HIV infections or to the diseases that result from these infections. Additional studies will identify response and complication rates of various anti-HCV and anti-HIV regimens in the setting of comprehensive clinical care of persons with hemophilia.

Study Type

Observational

Enrollment (Actual)

2565

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Sao Paulo, Brazil
        • Hospital Brigadeiro
      • Sao Paulo, Brazil
        • University of Sao Paulo
      • New Brunswick, Canada
        • South East Health Care Corporation
      • Lyons, France
        • Hospices Civils de Lyon
      • Bonn, Germany
        • University of Bonn
      • Athens, Greece
        • Laikon General Hospital of Athens
      • Florence, Italy
        • University of Florence
      • Milan, Italy
        • University de Milano
      • Stockholm, Sweden
        • Karolinska Institute St. Gorans Hospital
    • Arizona
      • Tucson, Arizona, United States, 85724
        • University of Arizona
    • California
      • Davis, California, United States, 95616
        • University of California, Davis
      • Orange, California, United States, 92613
        • Children's Hospital of Orange County
      • San Francisco, California, United States, 94143
        • University of California, San Francisco
    • Colorado
      • Denver, Colorado, United States, 80220-3706
        • University of Colorado
    • Delaware
      • Wilmington, Delaware, United States
        • Christiana Hospital
    • District of Columbia
      • Washington, District of Columbia, United States
        • Childrens National Medical Center
      • Washington, District of Columbia, United States, 20007-2197
        • Georgetown University
    • Georgia
      • Atlanta, Georgia, United States, 30322-1102
        • Emory University
    • Illinois
      • Chicago, Illinois, United States, 60612
        • University of Illinois
      • Chicago, Illinois, United States, 60614-3394
        • Childrens Memorial Hospital, Chicago
    • Indiana
      • Indianapolis, Indiana, United States
        • St. Vincent's Hospital
    • Louisiana
      • New Orleans, Louisiana, United States, 70112-2699
        • Tulane University
    • Michigan
      • Detroit, Michigan, United States, 48201
        • Wayne State University Hutzel Hospital
    • Minnesota
      • Minneapolis, Minnesota, United States, 55415
        • University of Minnesota
    • Mississippi
      • Jackson, Mississippi, United States, 39216
        • University of Mississippi
    • Missouri
      • Saint Louis, Missouri, United States, 63104
        • St. Louis University
    • New Mexico
      • Albuquerque, New Mexico, United States, 87131
        • University of New Mexico
    • New York
      • Buffalo, New York, United States
        • University of Buffalo
      • Lake Success, New York, United States, 11042
        • North Shore Long Island Jewish Health System
      • New York, New York, United States, 10021-4872
        • Cornell University
      • New York, New York, United States, 10029-0574
        • Mt. Sinai Medical Center
    • North Carolina
      • Chapel Hill, North Carolina, United States, 27599-7030
        • University of North Carolina
      • Winston-Salem, North Carolina, United States, 27103
        • Wake Forest University
    • Ohio
      • Cincinnati, Ohio, United States, 45267
        • University of Cincinnati
      • Cincinnati, Ohio, United States, 45229-3039
        • Childrens Hospital, Cinncinati
      • Columbus, Ohio, United States, 43210-1240
        • Ohio State University
      • Dayton, Ohio, United States, 45435
        • Wright State University
    • Oklahoma
      • Oklahoma City, Oklahoma, United States
        • University of Oklahoma
    • Pennsylvania
      • Hershey, Pennsylvania, United States, 17033
        • Milton Hershey Medical Center
      • Philadelphia, Pennsylvania, United States, 19104-6056
        • University of Pennsylvania
      • Philadelphia, Pennsylvania, United States, 19107-6541
        • Thomas Jefferson University
    • South Carolina
      • Columbia, South Carolina, United States, 29202
        • Palmentto Health Alliance
    • Tennessee
      • Memphis, Tennessee, United States, 38103
        • University of Tennessee
      • Nashville, Tennessee, United States, 37232
        • Vanderbilt University
    • Texas
      • Houston, Texas, United States, 77030
        • University of Texas, Houston
      • San Antonio, Texas, United States
        • University of Texas, San Antonio
    • Utah
      • Salt Lake City, Utah, United States, 84112
        • University of Utah
    • Wisconsin
      • Milwaukee, Wisconsin, United States
        • Childrens Hospital of Wisconsin

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

13 years and older (Child, Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

  • INCLUSION CRITERIA:

Must be registered patient with an inherited coagulation disorder at a participating MHCS-II center. Disorders include hemophilia A or B (congenital factor VIII or IX deficiency), deficiencies in other factors such as V or XI, and vonWillebrand's disease. (Unless noted otherwise, all of the disorders will collectively be referred to as hemophilia .) All such hemophilia and vonWillebrand s disease patients are to be recruited as study participants.

Since January 1, 1993, must have had at least one positive result on a licensed assay for HCV antibodies, HIV antibodies, or HIV RNA.

Must be at least 13 years of age at enrollment.

Must provide signed informed consent or, for minors, signed assent plus signed informed consent from the parent or guardian.

EXCLUSION CRITERIA:

Is not a patient with an inherited coagulation disorder.

Does not have a positive test for HCV antibodies, HIV antibodies, or HIV RNA on a licensed assay performed since January 1, 1993.

Is less than 13 years of age.

Lacks informed consent/assent.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: James J Goedert, M.D., National Cancer Institute (NCI)

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

April 27, 2001

Study Completion

April 2, 2013

Study Registration Dates

First Submitted

June 19, 2006

First Submitted That Met QC Criteria

June 19, 2006

First Posted (Estimate)

June 21, 2006

Study Record Updates

Last Update Posted (Actual)

December 17, 2019

Last Update Submitted That Met QC Criteria

December 14, 2019

Last Verified

April 2, 2013

More Information

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe